Walvax Biotechnology Gets Egypt Marketing Approval for 13-Valent Pneumococcal Vaccine

Walvax Biotechnology Gets Egypt Marketing Approval for 13-Valent Pneumococcal Vaccine

Morning Trend | Tonix Pharmaceuticals Holding experiences significant intraday volatility, is a rebound trend about to start?

Tonix Pharmaceuticals Holdings (TNXP.US) showed a significant surge in trading volume yesterday, with the previously stagnant small-cap pharmaceutical stocks experiencing a return of institutional investors, and community FOMO sentiment gradually rising. The stock price broke through short-term moving average resistance, igniting trading enthusiasm in the morning session, as bulls attempted to dominate the market. Although there are currently no major favorable policies in the pharmaceutical industry, speculation surrounding vaccine development and industry policy adjustments has resurfaced, transmitting to the small-cap biotech sector, where capital competition is rapidly heating up. Institutions quickly built positions and lifted prices in the low volatility zone, raising short-term attention. Technically, the daily K-line formed a large bullish candle, breaking through the upper band of the moving average system, with the MACD indicator also turning upward. The main funds made three upward pushes in intraday trading, with sufficient follow-up capital, indicating strong momentum. Today, attention should be paid to whether the gentle increase in volume can be sustained. If the short-term enthusiasm for chasing prices continues, it may ignite a rally in small-cap pharmaceutical stocks. Caution is needed against potential follow-up buying failing to sustain, which could lead to a quick cooling of the market as institutions take profits. For right-side traders, Tonix's intraday volatility today is an important signal for the initiation of a rebound trend

Sinovac: Signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, creating the largest international order for Chinese vaccines

Sinovac has signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese vaccine company to win the bid for this project. Sinovac will collaborate with Brazil's Tecpar Institute and Eurofarma to provide approximately 60 million doses of varicella and rabies vaccines to Brazil over the next ten years, with a contract amount exceeding 700 million USD, setting a record for the largest international order for a Chinese vaccine company

Mirxes Holding Signs Strategic RNA Medicine Partnership with Walvax

Mirxes Holding Co. Ltd. has signed an MOU with Walvax Biotechnology Co., Ltd. for a two-year strategic partnership. The collaboration aims to develop an RNA-centric preventive and precision medicine platform, focusing on joint development, clinical trials, registration, sales, and distribution of medical solutions. The goal is to advance early detection and preventive medicine. However, the collaboration under the MOU may or may not proceed.

U.S. Department of Health and Human Services Kennedy discusses the measles, mumps, and rubella vaccine: studying the feasibility of Trump's request to split it into separate injections